A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

October 7, 2011

New Hep C Treatment Guidelines Spell Out Incivek and Victrelis Use

Revised treatment guidelines from the American Association for the Study of Liver Diseases (AASLD) outline a significant change in the standard of care for people with genotype 1 chronic hepatitis C virus (HCV) infection. Instead of 48 weeks of pegylated interferon and ribavirin, treatment should also include one of the two new protease inhibitors (PIs)—either Incivek (telaprevir) or Victrelis (boceprevir)—with the length of therapy based on the results of viral load testing at different time points, depending on which PI is used.

Generally, people can discontinue therapy after 24 weeks, provided that their HCV viral load is undetectable after four weeks of therapy with a PI-inclusive regimen and that the virus remains undetectable for the remaining 20 weeks. Forty-eight weeks of treatment is still recommended for people who have cirrhosis, and for certain repeat treatment-takers (called null responders).

The updated AASLD guidelines, published in October in Hepatology, were issued for health care providers treating people with either Incivek or Victrelis, both of which were approved in May 2011 for use in combination with pegylated interferon and ribavirin. Incivek and Victrelis have dramatically increased cure rates for both first-time and repeat treatment-takers with chronic HCV genotype 1 infection. However, adding a third drug also makes HCV treatment more complicated for patients and their doctors.

Because of these complications, which include side effects and the development of HCV drug resistance to the protease inhibitors, AASLD recommends curtailing HCV treatment when it is very unlikely to work. Since these “stopping rules” differ for each drug, clear guidance is provided for when to stop therapy with both drugs.

The updated AASLD guidelines refer clinicians to the drugs’ labeling, or detailed package insert, for information on managing side effects, although the guidelines authors do provide their own guidance on managing anemia. Anemia is a common side effect from ribavirin and the HCV protease inhibitors. During hepatitis C treatment, if anemia develops, people are either treated with a red blood cell growth factor, such as Procrit (erythropoietin), or given a lower dose of ribavirin. The authors noted that cure rates were similar no matter which strategy was used to manage anemia. Since growth factors are costly and add side effects, AASLD recommends reducing the ribavirin dose to manage anemia while maintaining full-dose Incivek or Victrelis.

The guidelines also stress that clinicians and their patients can use IL-28B genotype testing—a blood test that can predict responses to HCV treatment with pegylated interferon, ribavirin and either Incivek or Victrelis—to gain more information on the likelihood of treatment effectiveness and the length of treatment. The authors caution, however, that IL-28B testing should not be used to withhold PIs from patients who have more favorable IL-28B results (for example, a “CC” genotype) and may be more likely to be cured with pegylated interferon and ribavirin alone, given that adding a PI significantly boosts cure rates in people with all IL-28B variations, including the harder-to-treat “CT” and “TT” genoytpes.

In the United States, an estimated 70 percent of people with hepatitis C have genotype 1. Before Incivek and Victrelis were approved, genotype 1 was difficult to treat; cure rates were less than 50 percent. Now, adding a protease inhibitor to pegylated interferon and ribavirin means that first-time treatment-takers are much more likely to be cured and they may be able to shorten treatment from 12 to six months. Hepatitis C protease inhibitors will also help people who were unsuccessfully treated in the past.

Marc G. Ghany, from the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, coauthored the updated recommendations with four colleagues. Ghany and his peers note that the update is “intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.”  

Ghany and his coauthors based their recommendations on their years of experience treating hepatitis C, and on published results from clinical trials. Their recommendations were based on the strength of available scientific evidence, as well as their potential risks and benefits. As such, these guidelines offer a thorough overview of the results from clinical trials, followed by specific recommendations for treating different groups of patients with each drug (since they are used differently).

Guidance on HCV treatment for special populations is limited because of a lack of data in people coinfected with HIV and hepatitis C, transplant recipients and people with decompensated cirrhosis, but the updated guidelines do address some key aspects of HCV treatment, such as how to determine the proper duration of treatment and the best time to stop it, as well as how to manage common side effects from the new drugs.

The guidelines also underscore the risk of combining Incivek or Victrelis with certain drugs that are commonly used by people with hepatitis C, and the guides provide additional resources for medical providers to help avoid drug interactions that can prevent drugs from working or increase their side effects.  

Unfortunately, the updated guidelines do not offer guidance on adherence, although it is crucial for successful HCV treatment. Incivek and Victrelis must be taken every eight hours, along with weekly injections and twice-daily ribavirin, often by people who already use additional medications.  

Now that a cure is more likely for people with HCV genotype 1, the demand for treatment is sure to increase, and more non-specialist providers may be called upon to care for HCV patients. The revised guidelines are an important resource, since they incorporate the latest research results into clear and handy recommendations for busy clinicians.

Search: Incivek, telaprevir, Victrelis, boceprevir, Merck, Vertex, genotype 1, AASLD, American Association for the Study of Lifer Diseases, guidelines, recommendations


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (3 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dave41
    Bethany
    Oklahoma


    TanyaB
    Delray Beach
    Florida


    youngbloodlatino
    Columbia
    Maryland


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.